

doi: 10.13241/j.cnki.pmb.2021.05.022

# 丙泊酚复合瑞芬太尼对高血压腹部手术患者血流动力学、炎症因子及认知功能的影响\*

徐健<sup>1</sup> 姚洪林<sup>1</sup> 何常佑<sup>1</sup> 任静华<sup>1</sup> 袁华<sup>2</sup> 刘成<sup>3</sup> 余得水<sup>1△</sup>

(1 四川大学华西医院宜宾医院麻醉科 四川 宜宾 644099;

2 四川省第四人民医院手术室 四川 成都 610016;3 四川大学华西医院麻醉科 四川 成都 610041)

**摘要 目的:**探讨丙泊酚复合瑞芬太尼对高血压腹部手术患者血流动力学、炎症因子及认知功能的影响。**方法:**选取2018年2月~2020年2月期间我院收治的高血压行腹部手术患者150例,上述患者根据随机数字表法分为对照组(n=75)和研究组(n=75),对照组患者予以丙泊酚维持麻醉,研究组予以丙泊酚复合瑞芬太尼维持麻醉,比较两组患者围术期指标、血流动力学、炎症因子及认知功能情况。**结果:**研究组呼吸恢复时间、拔气管导管时间、苏醒时间均短于对照组( $P<0.05$ )。研究组手术结束(T1)~拔管后(T3)时间点心率(HR)、收缩压(SBP)、舒张压(DBP)均高于对照组( $P<0.05$ )。研究组术后3d、术后5d白介素-1(IL-1)、白介素-6(IL-6)、肿瘤坏死因子- $\alpha$ (TNF- $\alpha$ )低于对照组( $P<0.05$ )。研究组术后1d、术后3d、术后5d简易智力状态检查表(MMSE)评分均高于对照组( $P<0.05$ )。研究组术后1d、术后3d的POCD发生率低于对照组( $P<0.05$ )。**结论:**高血压腹部手术患者麻醉维持选用瑞芬太尼复合丙泊酚方案,可维持机体血流平稳,减轻机体炎症应激及认知功能损害,具有较高的临床应用价值。

**关键词:**丙泊酚;瑞芬太尼;高血压;腹部手术;血流动力学;炎症因子;认知功能**中图分类号:**R544.1;R656 **文献标识码:**A **文章编号:**1673-6273(2021)05-907-04

## Effects of Propofol Combined with Remifentanil on Hemodynamics, Inflammatory Factors and Cognitive Function in Patients Undergoing Abdominal Surgery for Hypertension\*

XU Jian<sup>1</sup>, YAO Hong-lin<sup>1</sup>, HE Chang-you<sup>1</sup>, REN Jing-hua<sup>1</sup>, YUAN Hua<sup>2</sup>, LIU Cheng<sup>3</sup>, YU De-shui<sup>1△</sup>

(1 Department of Anesthesiology, Yibin Hospital of West China Hospital of Sichuan University, Yibin, Sichuan, 644099, China;

2 Operation Room, The Fourth People's Hospital of Sichuan Province, Chengdu, Sichuan, 610016, China;

3 Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China)

**ABSTRACT Objective:** To investigate the effect of propofol combined with remifentanil on hemodynamics, inflammatory factors and cognitive function in patients with hypertension undergoing abdominal surgery. **Methods:** From February 2018 to February 2020, 150 patients who hypertension underwent abdominal surgery in our hospital were selected. The patients were divided into control group (n=75) and study group (n=75) according to the random number table method. The patients in the control group were given propofol maintenance anesthesia, while the patients in the study group were given propofol combined with remifentanil maintenance anesthesia. The perioperative indexes, hemodynamics, inflammatory factors and cognitive function of the two groups were compared. **Results:** The respiratory recovery time, tracheal catheter extraction time and resuscitation time of the study group were shorter than those of the control group ( $P<0.05$ ). The heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the time point between end of the operation (T1) and after extubation (T3) were all higher in the study group than in the control group ( $P<0.05$ ). Interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) of the study group at 1d after operation, 3d after operation, 5d after operation were lower than those of the control group ( $P<0.05$ ). The scores of mini-mental state examination (MMSE) of the study group were higher than those of the control group ( $P<0.05$ ). The incidence of POCD of the study group at 1d after operation, 3d after operation were lower than those of the control group ( $P<0.05$ ). **Conclusion:** Remifentanil for maintenance of anesthesia in patients with hypertensive abdominal surgery conforms to the propofol scheme, which can maintain the stable blood flow, reduce the body's inflammatory stress and cognitive impairment, and has high clinical application value.

**Key words:** Propofol; Remifentanil; Hypertensive; Abdominal surgery; Hemodynamics; Inflammatory factors; Cognitive function**Chinese Library Classification(CLC):** R544.1; R656 **Document code:** A**Article ID:** 1673-6273(2021)05-907-04

\* 基金项目:国家自然科学基金面上项目(81071771);四川省卫生和计划生育委员会科研项目(150254)

作者简介:徐健(1988-),男,本科,主治医师,研究方向:临床麻醉,E-mail:xujian2484@163.com

△ 通讯作者:余得水(1983-),男,博士,副主任医师,研究方向:手术麻醉,E-mail:15680391118@163.com

(收稿日期:2020-07-26 接受日期:2020-08-21)

## 前言

高血压病是临床常见的退行性疾病,以动脉血压升高为主要临床特征,好发于中老年群体<sup>[1-3]</sup>。此类患者在接受外科手术治疗时,对麻醉药物代谢速度降低,心血管疾病的发生风险明显高于正常群体,因而对手术中的麻醉要求也随之提高<sup>[4-6]</sup>。丙泊酚、瑞芬太尼均是目前临幊上应用较为广泛的静脉麻醉药物,两种药物在多种外科手术中均有较好的疗效,均具有镇痛效果好、可控性好、作用时间短等特点<sup>[7,8]</sup>。但有关其联合应用于高血压腹部手术患者的相关报道并不十分多见。鉴于此,本研究通过探讨丙泊酚复合瑞芬太尼对高血压腹部手术患者的影响,以期为临床高血压腹部手术麻醉方法的选择提供参考。

## 1 资料与方法

### 1.1 一般资料

选取 2018 年 2 月 ~2020 年 2 月期间我院收治的行腹部手术的高血压患者 150 例,此研究已获取我院伦理学委员会批准进行。纳入标准:(1)美国麻醉协会(American Society of Anesthesiology,ASA)分级 I~II 级,收缩压(SBP)≤ 179 mmHg,舒张压(DBP)≤ 109 mmHg<sup>[9]</sup>;(2)患者及其家属知情本次研究且签署了同意书;(3)符合手术指征,对本次研究用药耐受者;(4)手术均由同一组医师完成操作。排除标准:(1)合并凝血功能障碍者;(2)合并心肝肾等脏器功能障碍者;(3)既往有腹部手术史者;(4)合并精神疾患,无法正常沟通交流者;(5)内分泌系统疾病者。上述患者根据随机数字表法分为对照组(n=75,丙泊酚维持麻醉)和研究组(n=75,丙泊酚复合瑞芬太尼维持麻醉),其中对照组男 36 例,女 39 例,年龄 39~62 岁,平均(50.38±4.27)岁;体质量指数 20.5~26.2 kg/m<sup>2</sup>,平均(23.15±0.83)kg/m<sup>2</sup>;ASA 分级 I 级 38 例,II 级 37 例;腹部手术类型:其中肝脏、胆囊手术 21 例,胃、十二指肠手术 26 例,结肠手术 20 例,其他手术 8 例。研究组男 34 例,女 41 例,年龄 42~65 岁,平均(50.96±4.05)岁;体质量指数 20.9~25.8 kg/m<sup>2</sup>,平均(23.23±0.75)kg/m<sup>2</sup>;ASA 分级 I 级 40 例,II 级 35 例;腹部手术类型:其中肝脏、胆囊手术 23 例,胃、十二指肠手术 28 例,结肠手术 17 例,其他手术 7 例。两组一般资料对比无统计学差异( $P>0.05$ )。

### 1.2 方法

所有患者术前均禁饮、禁食 6 h,入室后开放静脉通道,监测患者心电图、血压、心率(Heart rate,HR)。麻醉诱导:依次静脉滴注咪达唑仑(宜昌人福药业有限责任公司生产,国药准字 H20067041,规格:2 mL:10 mg)0.05 mg/kg,丙泊酚乳状注射液(四川国瑞药业有限责任公司,国药准字 H20030114,规格:50 mL:0.5 g)2 mg/kg,舒芬太尼(宜昌人福药业有限责任公司生产,国药准字 H20054171,规格:1 mL: 50 μg)0.5 μg/kg,顺式阿曲库铵(江苏恒瑞医药股份有限公司生产,国药准字 H20060869,规格:10 mg)0.15 mg/kg,诱导成功后插入气管导管,连接麻醉机控制呼吸,呼吸 12 次/min,二氧化碳呼气末分压 35~45 mmHg,呼吸比 1:2,调节氧流量 2 L/min。对照组患者仅用丙泊酚 TCI:2~4 μg/mL 维持麻醉,研究组则给予丙泊酚 TCI:2~4 μg/mL 联合注射用盐酸瑞芬太尼 [宜昌人福药业有限责任公司生产,国药准字 H20030197,规格:1 mg (以瑞芬太尼 C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub> 计)]

TCI:2~4 ng/mL 维持麻醉。在术中密切监测患者的 HR 与血压,对于血压值超过基础值 10% 的患者给予硝酸甘油(河南润弘制药股份有限公司,国药准字 H20057216,规格:1 mL: 5 mg)进行降压治疗;对于 HR 超过 100 次/min 的患者给予艾司洛尔(齐鲁制药有限公司,国药准字 H19991059,规格:10 mL: 0.1 g)进行控制心率治疗。手术缝皮时停用所有麻醉药物。

### 1.3 观察指标

**1.3.1 围术期指标** 记录两组围术期指标,包括呼吸恢复时间、苏醒时间、拔气管导管时间。

**1.3.2 血流动力学指标** 记录两组手术前(T0)、手术结束(T1)、拔管时(T2)和拔管后(T3)的 HR、收缩压(Systolic blood pressure,SBP)和舒张压(Diastolic blood pressure,DBP)。

**1.3.3 炎症因子** 抽取患者 T0、术后 3d、术后 5d 时间点的肘静脉血 6 mL,经 3600 r/min 离心 12 min,离心半径 12 cm,分离上清液置于 -30°C 冰箱中待测。选用武汉华美生物科技有限公司试剂盒,根据试剂盒说明书步骤进行操作,采用酶联免疫吸附法检测白介素-1(Interleukin-1,IL-1)、白介素-6(Interleukin-6,IL-6)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)水平。

**1.3.4 认知功能** 于术前、术后 1d、术后 3d、术后 5d 采用简易智力状态检查表(Mini-mental state examination,MMSE)<sup>[10]</sup>评分评价患者认知功能状况。MMSE 评分主要包括定向力检测、记忆力检测、注意力检测、语言功能检测、计算力检测、空间位置觉检测等,总分 30 分,分数越高,认知功能越好。统计两组患者术后认知功能障碍(Postoperative cognitive dysfunction,POCD)发生率,其中 MMSE 评分 <27 分即表示发生 POCD。

### 1.4 统计学方法

采用 SPSS20.0 进行数据分析。计量资料采用平均值±标准差来表示,采用 t 检验。计数资料采用%表示,通过 χ<sup>2</sup> 检验,检验水准为 α=0.05。

## 2 结果

### 2.1 两组围术期指标比较

研究组呼吸恢复时间、苏醒时间、拔气管导管时间均短于对照组( $P<0.05$ );详见表 1。

### 2.2 两组血流动力学指标比较

两组 T0 时间点 HR、SBP、DBP 比较无差异( $P>0.05$ );两组 T0~T3 时间点 HR、SBP、DBP 呈先降低后升高趋势( $P<0.05$ );研究组 T1~T3 时间点 HR、SBP、DBP 均高于对照组( $P<0.05$ );详见表 2。

### 2.3 两组炎症因子比较

两组 T0 时间点 IL-1、IL-6、TNF-α 比较无差异( $P>0.05$ );两组 T0~术后 5d IL-1、IL-6、TNF-α 呈先升高后降低趋势( $P<0.05$ );研究组术后 3d、术后 5d IL-1、IL-6、TNF-α 低于对照组( $P<0.05$ );详见表 3。

### 2.4 两组 MMSE 评分比较

两组术前 MMSE 评分比较无差异( $P>0.05$ );两组术前~术后 5d MMSE 评分呈下降后升高趋势( $P<0.05$ );研究组术后 1d、术后 3d、术后 5d MMSE 评分均高于对照组( $P<0.05$ );详见表 4。

表 1 两组围术期指标比较( $\bar{x} \pm s$ , min)  
Table 1 Comparison of perioperative indicators between the two groups( $\bar{x} \pm s$ , min)

Groups	Respiratory recovery time	Resuscitation time	Tracheal catheter extraction time
Control group(n=75)	8.62±1.21	18.87±2.35	22.24±2.78
Study group(n=75)	4.97±0.96	13.22±2.86	15.96±2.35
t	20.465	13.219	14.941
P	0.000	0.000	0.000

表 2 两组血流动力学指标比较( $\bar{x} \pm s$ )  
Table 2 Comparison of hemodynamic indexes between the two groups( $\bar{x} \pm s$ )

Groups	Time point	HR( beats/min )	SBP( mmHg )	DBP( mmHg )
Control group(n=75)	T0	82.41±6.45	150.85±8.33	99.48±7.36
	T1	63.35±6.19 <sup>a</sup>	87.19±7.25 <sup>a</sup>	78.04±7.52 <sup>a</sup>
	T2	69.21±5.27 <sup>ab</sup>	94.01±9.20 <sup>ab</sup>	85.68±6.97 <sup>ab</sup>
	T3	75.88±6.49 <sup>abc</sup>	101.78±7.33 <sup>abc</sup>	91.74±7.21 <sup>abc</sup>
Study group(n=75)	T0	82.28±7.33	149.33±7.13	98.53±8.09
	T1	69.41±6.94 <sup>ad</sup>	94.36±7.18 <sup>ad</sup>	82.35±7.36 <sup>ad</sup>
	T2	75.95±5.84 <sup>abd</sup>	101.39±8.39 <sup>abd</sup>	90.46±6.41 <sup>abd</sup>
	T3	80.15±6.48 <sup>bcd</sup>	107.57±8.11 <sup>bcd</sup>	97.19±7.59 <sup>bcd</sup>

Notes: compared with T0 time point, <sup>a</sup>P<0.05; compared with T1 time point, <sup>b</sup>P<0.05; compared with T2 time point, <sup>c</sup>P<0.05; compared with the control group, <sup>d</sup>P<0.05.

表 3 两组炎症因子水平比较( $\bar{x} \pm s$ )  
Table 3 Comparison of levels of inflammatory factors between the two groups( $\bar{x} \pm s$ )

Groups	Time point	IL-1(pg/mL)	IL-6(pg/mL)	TNF- $\alpha$ (ng/mL)
Control group(n=75)	T0	54.41±8.26	85.86±6.36	72.36±6.35
	3d after operation	82.33±9.23 <sup>a</sup>	112.31±7.57 <sup>a</sup>	95.39±6.41 <sup>a</sup>
	5d after operation	69.25±7.89 <sup>ab</sup>	101.59±8.21 <sup>ab</sup>	86.25±7.74 <sup>ab</sup>
Study group(n=75)	T0	53.23±9.78	85.62±6.10	71.97±7.46
	3d after operation	73.94±7.19 <sup>ac</sup>	102.94±6.89 <sup>ac</sup>	86.72±8.44 <sup>ac</sup>
	5d after operation	62.03±8.01 <sup>abc</sup>	93.41±7.73 <sup>abc</sup>	79.76±7.52 <sup>abc</sup>

Notes: compared with before operation, <sup>a</sup>P<0.05; compared with 1d after operation, <sup>b</sup>P<0.05; compared with 3d after operation, <sup>c</sup>P<0.05.

表 4 两组 MMSE 评分比较( $\bar{x} \pm s$ , 分)  
Table 4 Comparison of MMSE scores between the two groups( $\bar{x} \pm s$ , scores)

Groups	Before operation	1d after operation	3d after operation	5d after operation
Control group(n=75)	29.23±0.27	25.25±0.38 <sup>a</sup>	27.76±0.23 <sup>ab</sup>	28.04±0.21 <sup>abc</sup>
Study group(n=75)	29.18±0.28	26.81±0.26 <sup>a</sup>	28.02±0.22 <sup>ab</sup>	29.12±0.24 <sup>bc</sup>
t	1.113	29.342	7.075	29.329
P	0.267	0.000	0.000	0.000

Notes: compared with before operation, <sup>a</sup>P<0.05; compared with 1d after operation, <sup>b</sup>P<0.05; compared with 3d after operation, <sup>c</sup>P<0.05.

## 2.5 两组 POCD 发生情况比较

研究组术后 1d、术后 3dPOCD 发生率低于对照组( $P<0.05$ ); 两组术后 5dPOCD 发生率比较差异无统计学意义( $P>0.05$ ); 详见表 5。

## 3 讨论

高血压是指静息状态下动脉 SBP≥140mmHg 和 (或) DBP≥90mmHg, 多发于中老年群体, 并伴有脂代谢、糖代谢紊乱现象<sup>[11,12]</sup>。近年来, 随着人们生活结构的改变, 以及人口老龄化的加剧, 高血压的发病率呈不断升高趋势<sup>[13]</sup>。近年来需要行腹部外科手术的高血压患者人数不断增加, 由于高血压患者泵血功能和心脏储血功能降低<sup>[14,15]</sup>。加之高血压患者多伴有不同

表 5 两组术后 POCD 发生情况比较例(%)  
Table 5 Comparison of postoperative POCD in the two groups n(%)

Groups	1d after operation	3d after operation	5d after operation
Control group(n=75)	36(48.00)	25(33.33)	9(12.00)
Study group(n=75)	24(32.00)	11(14.67)	3(4.00)
$\chi^2$	4.000	7.164	3.265
P	0.046	0.007	0.071

程度的并发症,易导致患者术中血流波动过大,术后苏醒时间延长,在接受麻醉手术时风险明显增加<sup>[16]</sup>。此外,不同麻醉药物对患者脑氧代谢的影响不同,对此其造成的脑神经损伤程度也有区别,不少患者术后可出现POCD现象<sup>[17]</sup>。丙泊酚是一种新型静脉麻醉药物,具有起效迅速、苏醒迅速的特点。但既往有报道表明<sup>[18]</sup>,丙泊酚在麻醉维持期有抑制患者呼吸、影响患者血压等不良作用。瑞芬太尼是一种新型μ型阿片受体激动剂,其镇痛效果显著,在体内的代谢清除过程不受麻醉诱导剂量的影响,常用于麻醉诱导和麻醉维持镇痛<sup>[19]</sup>。

本次研究结果显示,两组患者术中均出现不同程度的血流波动,但研究组的血流波动程度明显更轻。分析其原因,丙泊酚亲脂性高,进入人体后可迅速分布至中枢神经系统和周围组织<sup>[20]</sup>。而瑞芬太尼可以剂量依赖性地降低血压和HR,可通过舒张血管平滑肌进而抑制儿茶酚胺的释放,有效抑制气管插管和手术应激时的高血压反应<sup>[21,22]</sup>。当瑞芬太尼与丙泊酚联合用药时,产生协同作用,进一步维持血流动力学稳定<sup>[23]</sup>。而研究组呼吸恢复时间、苏醒时间、拔气管导管时间均短于对照组,提示两种药物联合使用可促进患者快速苏醒。究其原因可能在于瑞芬太尼血气分配系数低,对机体的循环系统影响较小。手术创伤作为一种特殊的创伤形式可激活机体炎症因子,IL-1、IL-6、TNF-α均是急性炎症期反应的重要指标,可评估患者术后创伤严重程度<sup>[24,25]</sup>。本次研究中两组患者均存在炎症应激,但丙泊酚复合瑞芬太尼方案者的炎症应激反应程度更轻。其可能机制在于:复合用药可减少丙泊酚的使用剂量,进而减轻丙泊酚带来的呼吸系统和心血管系统的抑制;加之瑞芬太尼还可抑制淋巴细胞增殖,减轻炎症应激反应<sup>[26,27]</sup>。研究中丙泊酚复合瑞芬太尼方案还可保护患者认知功能,减少POCD发生率。这可能是因为瑞芬太尼起效迅速,在人体1min左右内即可达到血-脑平衡,维持脑氧正常代谢,不受血浆胆碱酯酶的影响,且排泄速度快,易于从人体消除,减少对人体神经中枢的损害,从而提高手术麻醉的质量。

综上所述,高血压腹部手术患者麻醉维持选用丙泊酚复合瑞芬太尼方案,可维持机体血流平稳,减轻机体炎症应激及认知功能损害,具有较高的临床应用价值。

#### 参考文献(References)

- Günay N, Pınarbaşı AS, Dursun İ, et al. Calcified renal artery aneurism in the right kidney causing hypertension [J]. Saudi J Kidney Dis Transpl, 2020, 31(1): 266-270
- Di Martino M, de la Hoz Rodríguez A, Real Martínez Y, et al. Left-sided portal hypertension due to retroperitoneal fibrosis treated with an oesophagus preserving, modified Sugiura procedure [J]. Ann R Coll Surg Engl, 2020, 102(2): e48-e50
- Soyaltın E, Alaygut D, Alparslan C, et al. A rare cause of neonatal hypertension: Congenital mesoblastic nephroma [J]. Turk J Pediatr, 2018, 60(2): 198-200
- Nazer R, Albarrati A, Ullah A, et al. Intra-abdominal hypertension in obese patients undergoing coronary surgery: A prospective observational study[J]. Surgery, 2019, 166(6): 1128-1134
- Elkrief L, Compagnon P, Andres A, et al. Abdominal surgery in patients with portal hypertension: clinical implication and management[J]. Rev Med Suisse, 2019, 15(655): 1217-1220
- Lin J, Liu Q, Liang Z, et al. Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension [J]. Wideochir Inne Tech Maloinwazyjne, 2019, 14(2): 187-194
- Sujata N, Tobin R, Tamhankar A, et al. A randomised trial to compare the increase in intracranial pressure as correlated with the optic nerve sheath diameter during propofol versus sevoflurane-maintained anaesthesia in robot-assisted laparoscopic pelvic surgery [J]. J Robot Surg, 2019, 13(2): 267-273
- Kwon JH, Shin YH, Gil NS, et al. Effect-site concentration of remifentanil for smooth emergence from sevoflurane anesthesia in patients undergoing endovascular neurointervention [J]. PLoS One, 2019, 14(6): e0218074
- 高铁梅, 范顺翠, 吴冰清, 等. 不同ASA分级老年患者术后心脏事件的观察[J]. 临床麻醉学杂志, 2017, 33(9): 909-910
- 张继清, 梁吉文, 陆源琴. 老年上腹部手术患者全麻术后认知功能障碍的发生因素[J]. 兰州大学学报(医学版), 2013, 39(1): 58-61
- 关信民, 邹月柳, 吕嘉春, 等. 藏族原发性高血压患者血管内皮功能与糖脂代谢指标和血压变异性的关系 [J]. 现代生物医学进展, 2018, 18(22): 4261-4264, 4289
- Nelson JA, Alsayed M, Milas M. The role of parathyroidectomy in treating hypertension and other cardiac manifestations of primary hyperparathyroidism[J]. Gland Surg, 2020, 9(1): 136-141
- Saito T, Kasai H, Sugiura T, et al. Effects of pulmonary endarterectomy on pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension, evaluated by interventricular septum curvature [J]. Pulm Circ, 2020, 10 (1): 2045894019897502
- Troisi RI, Vanlander A, Giglio MC, et al. Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial [J]. Ann Surg, 2019, 269 (6): 1025-1033
- He L, Yi C, Hou Z, et al. Intraabdominal hypertension/abdominal compartment syndrome after pelvic fractures: How they occur and what can be done? [J]. Injury, 2019, 50(4): 919-925

- Cancer[J]. J Clin Oncol, 2017, 35(1): 48-55
- [14] 李海燕, 李玉娟, 曹淑琴, 等. 培美曲塞联合顺铂对老年Ⅲ~Ⅳ期非小细胞肺癌患者血清CEA,CYFRA21-1,p-ERK,VEGF及Annexin II水平的影响[J]. 现代生物医学进展, 2017, 17(19): 3758-3761
- [15] Gao X, Chen G, Cai H, et al. Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway [J]. Biomed Pharmacother, 2020, 122(10): 109710
- [16] Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis[J]. Mol Oncol, 2017, 11(1): 28-39
- [17] Liao TT, Yang MH. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness[J]. Mol Oncol, 2017, 11(7): 792-804
- [18] Chen X, Wang L, Li P, et al. Dual TGF- $\beta$  and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 $^+$  T cell response in esophageal squamous cell carcinoma [J]. Int J Cancer, 2018, 143(10): 2561-2574
- [19] Yi JS, Ready N, Healy P, et al. Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab [J]. Clin Cancer Res, 2017, 23(24): 7474-7482
- [20] Pan SH, Su KY, Spiessens B, et al. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients [J]. Asia Pac J Clin Oncol, 2017, 13(5): 212-223
- [21] Kim MH, Jeong YJ, Cho HJ, et al. Delphinidin inhibits angiogenesis through the suppression of HIF-1 $\alpha$  and VEGF expression in A549 lung cancer cells[J]. Oncol Rep, 2017, 37(2): 777-784
- [22] Zhao Y, Wang XX, Wu W, et al. EZH2 regulates PD-L1 expression via HIF-1 $\alpha$  in non-small cell lung cancer cells [J]. Biochem Biophys Res Commun, 2019, 517(2): 201-209
- [23] Chi Y, Luo Q, Song Y, et al. Circular RNA circPIP5K1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/HIF-1 $\alpha$  regulation[J]. J Cell Biochem, 2019, 120(11): 19019-19030
- [24] Zhao FL, Qin CF. EGF promotes HIF-1 $\alpha$  expression in colorectal cancer cells and tumor metastasis by regulating phosphorylation of STAT3[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3): 1055-1062
- [25] Yu X, Hu L, Li S, et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1 $\alpha$  via miR-143-5p[J]. Cell Death Dis, 2019, 10(4): 280
- [26] Muller A, Gasch J, Albring KF, et al. Interplay of transcription factors STAT3,STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells [J]. Neoplasma, 2019, 66(3): 357-366
- [27] Hannafon BN, Gin AL, Xu YF, et al. Metastasis-associated protein 1 (MTA1) is transferred by exosomes and contributes to the regulation of hypoxia and estrogen signaling in breast cancer cells [J]. Cell Commun Signal, 2019, 17(1): 13
- [28] Kumar A, Dhar S, Campanelli G, et al. MTA1 drives malignant progression and bone metastasis in prostate cancer [J]. Mol Oncol, 2018, 12(9): 1596-1607
- [29] Lv ZY, Zhao ZS, Ye ZY, et al. Metastasis-associated protein 1 (MTA1) in gastric cancer tissues is positively associated with poorer prognosis[J]. Pathol Res Pract, 2018, 214(4): 536-541
- [30] Ma K, Fan Y, Dong X, et al. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer [J]. Oncotarget, 2017, 8(24): 38825-38840

(上接第 910 页)

- [16] Angelico R, Pietrobattista A, Candusso M, et al. Primary Prophylaxis for Gastrointestinal Bleeding in Children With Biliary Atresia and Portal Hypertension Candidates for Liver Transplantation: A Single-Center Experience[J]. Transplant Proc, 2019, 51(1): 171-178
- [17] 郭红利, 张先杰, 周裕凯, 等. 不同麻醉药物对老年骨科手术患者术后认知功能的影响及其机制 [J]. 中国医院药学杂志, 2017, 37(7): 643-646
- [18] Yu Y, Qi SL, Zhang Y. Role of combined propofol and sufentanil anesthesia in endoscopic injection sclerotherapy for esophageal varices[J]. World J Gastroenterol, 2017, 23(44): 7875-7880
- [19] Wang C, Li L, Xu H, et al. Effect of desflurane-remifentanil or sevoflurane-remifentanil on early recovery in elderly patients: a meta-analysis of randomized controlled trials[J]. Pharmazie, 2019, 74(4): 201-205
- [20] Zhang H, Fang B, Zhou W. The efficacy of dexmedetomidine-remifentanil versus dexmedetomidine-propofol in children undergoing flexible bronchoscopy: A retrospective trial[J]. Medicine (Baltimore), 2017, 96(1): e5815
- [21] Liu M, Wu H, Yang D, et al. Effects of small-dose remifentanil combined with index of consciousness monitoring on gastroscopic polypectomy: a prospective, randomized, single-blinded trial [J]. Trials, 2018, 19(1): 392
- [22] Ren LQ, Sun XX, Guan Y. Effects of sevoflurane or propofol combined with remifentanil anesthesia on clinical efficacy and stress response in pregnant women with pregnancy-induced hypertension[J]. Eur Rev Med Pharmacol Sci, 2018, 22(6): 1825-1829
- [23] Kim TK, Hong DM, Lee SH, et al. Effect-site concentration of remifentanil required to blunt haemodynamic responses during tracheal intubation: A randomized comparison between single- and double-lumen tubes[J]. J Int Med Res, 2018, 46(1): 430-439
- [24] 孙桂芳, 黄永生. 妇科手术后早期炎性肠梗阻患者的临床特征及治疗策略[J]. 实用临床医药杂志, 2019, 23(20): 95-97, 101
- [25] 杨志明, 胡帮红, 杨波, 等. 微创引流术对老年高血压脑出血患者炎性介质、脑出血标志物水平的影响[J]. 疑难病杂志, 2018, 17(5): 437-441
- [26] Li X, Wang X, Jin S, et al. The safety and efficacy of dexmedetomidine-remifentanil in children undergoing flexible bronchoscopy: A retrospective dose-finding trial [J]. Medicine (Baltimore), 2017, 96(11): e6383
- [27] Smischney NJ, Nicholson WT, Brown DR, et al. Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial[J]. J Trauma Acute Care Surg, 2019, 87(4): 883-891